CG Oncology, Inc. $CGON Shares Sold by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC trimmed its holdings in shares of CG Oncology, Inc. (NASDAQ:CGON) by 15.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 426,019 shares of the company’s stock after selling 77,507 shares during the period. TimesSquare Capital Management LLC’s holdings in CG Oncology were worth $17,688,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of CGON. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of CG Oncology during the fourth quarter worth $27,000. Strengthening Families & Communities LLC acquired a new stake in shares of CG Oncology during the third quarter worth $40,000. Comerica Bank raised its holdings in shares of CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after purchasing an additional 515 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of CG Oncology by 33.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock worth $163,000 after purchasing an additional 972 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in shares of CG Oncology by 159.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company’s stock worth $182,000 after purchasing an additional 4,288 shares during the period. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Stock Up 0.6%

CGON stock opened at $63.30 on Wednesday. CG Oncology, Inc. has a fifty-two week low of $23.65 and a fifty-two week high of $75.50. The firm’s 50-day simple moving average is $67.14 and its 200 day simple moving average is $54.30. The stock has a market cap of $5.58 billion, a PE ratio of -27.17 and a beta of 0.41.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The company had revenue of $1.08 million for the quarter, compared to analyst estimates of $0.45 million. Equities analysts forecast that CG Oncology, Inc. will post -2.89 EPS for the current fiscal year.

Insider Buying and Selling at CG Oncology

In related news, Director James Mulay sold 15,600 shares of the stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $73.01, for a total value of $1,138,956.00. Following the sale, the director owned 15,600 shares of the company’s stock, valued at $1,138,956. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on CGON shares. JPMorgan Chase & Co. increased their target price on shares of CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Wolfe Research started coverage on shares of CG Oncology in a report on Tuesday. They set a “peer perform” rating on the stock. Royal Bank Of Canada increased their target price on shares of CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a report on Monday, April 20th. Finally, Wedbush increased their target price on shares of CG Oncology from $77.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.73.

CG Oncology Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.